Identification and validation of an immune-related lncRNAs signature to predict the overall survival of ovarian cancer

Abstract

Ovarian cancer (OC) is the most lethal gynecological cancer in women. Studies had reported that immune-related lncRNAs signatures were valuable in predicting the survival and prognosis of patients with various cancers. In our study, the prognostic value of immune-related lncRNAs was investigated in OC patients from TCGA-RNA-seq cohort (n=378) and HG-U133_Plus_2 cohort (n=590), respectively. Pearson correlation analysis was implemented to screen the immune-related lncRNA and then univariate Cox regression analysis was performed to explore their prognostic value in OC patients. Five prognostic immune-related lncRNAs were identified as prognostic lncRNAs. Besides, they were inputted into a LASSO Cox regression to establish and validate an immune-related lncRNA prognostic signature in TCGA-RNA-Seq cohort and HG-U133_Plus_2 cohort, respectively. Based on the best cut-off value of risk score, patients were divided into high- and low-risk groups. Survival analysis suggested that patients in the high-risk group had a worse overall survival (OS) than those in the low-risk group in both cohorts. The association between clinicopathological feathers and risk score was then evaluated by using stratification analysis. Moreover, we constructed a nomogram based on risk score, age and stage, which had a strong ability to forecast the OS of the OC patients. The influence of risk score on immune infiltration and immunotherapy response were assessed and the results suggested that patients with high-risk score might recruit multiple immune cells and stromal cells, leading to facilitating immune surveillance evasive. Ultimately, we demonstrated that the risk model was associated with chemotherapy response of multiple antitumor drugs, especially for paclitaxel, metformin and veliparib, which are commonly used in treating OC patients. In conclusion, we constructed a novel immune-related lncRNA signature, which had a potential prognostic value for OC patients and might facilitate personalized counselling for immunotherapy and chemotherapy.

Dissecting the role of lactate metabolism LncRNAs in the progression and immune microenvironment of osteosarcoma

“…We combined the TARGET and GTEx databases and used Pearson correlation analysis (coefficient set to >0.3, p value set to <0.001) to create a prognostic predictive signature for osteosarcoma comprising five lactate metabolism-associated lncRNAs for the first time based on the experience of previous scholars studying related lncRNAs [38] , [39] , [40] , [41] . In the correlation node network graph of the eight DELRLs, RP5-1011O1.2 was negatively correlated with other genes, while all other genes were positively correlated with each other, indicating that RP5-1011O1.2 may be a security gene for patients with osteosarcoma.…”

Construction of Ovarian Cancer Prognostic Model Based on the Investigation of Ferroptosis-Related lncRNA

“…The ROC curves of different clinical factors and the FL_Score for predicting the 5-year survival rate (Figure 4E) showed that the AUC values of the FL_Score, age, and stage were 0.681, 0.578, and 0.65, respectively, indicating that FL_Score has a better capability to predict OV prognosis when compared with the other clinical factors. We also compared the 1-, 3-, and 5-year AUC values of FL_Score with 18 other published prognostic signatures [9,10,[28][29][30][31][32][33][34][35][36][37][38][39][40][41][42] for patients with OV in TCGA database to test the prognostic performance of our FL_Score signature (Figure 5). These 18 signatures exhibited associations with some biological features, including N6-methyladenosine, pyroptosis, autophagy, and others.…”

A Novel Prognostic Chemokine-Related lncRNAs Signature Associated with Immune Landscape in Colon Adenocarcinoma

“…Many lncRNAs are involved in gene regulation and various biological functions at the transcriptional, posttranscriptional, and epigenetic levels, including the recent discovery that some lncRNAs can encode small peptides/proteins [ 6 ]. Accumulating evidence showed that aberrant expression of lncRNAs is not only associated with tumor malignancy but many chemically modified lncRNAs have been validated in various cancers [ 7 , 8 ]. There may be interactions between these modifications, with some competitive compensation.…”